Ming‐Mo Hou

1.6k total citations
52 papers, 913 citations indexed

About

Ming‐Mo Hou is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ming‐Mo Hou has authored 52 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 19 papers in Public Health, Environmental and Occupational Health and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ming‐Mo Hou's work include Palliative Care and End-of-Life Issues (18 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). Ming‐Mo Hou is often cited by papers focused on Palliative Care and End-of-Life Issues (18 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). Ming‐Mo Hou collaborates with scholars based in Taiwan, United States and China. Ming‐Mo Hou's co-authors include Jen‐Shi Chen, Wen‐Chi Chou, Wen‐Cheng Chang, Siew Tzuh Tang, Yoon‐Koo Kang, Chiun Hsu, Tae‐You Kim, Masatoshi Kudo, Fur‐Hsing Wen and Chia‐Hsun Hsieh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ming‐Mo Hou

50 papers receiving 908 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming‐Mo Hou Taiwan 15 427 343 197 162 147 52 913
Ho-Yeong Lim South Korea 11 209 0.5× 348 1.0× 144 0.7× 110 0.7× 99 0.7× 13 691
Deborah Jaffe United States 6 415 1.0× 204 0.6× 43 0.2× 93 0.6× 145 1.0× 6 1.0k
Jeremy Jones United States 11 426 1.0× 68 0.2× 33 0.2× 132 0.8× 124 0.8× 54 758
Weng Ng Australia 20 655 1.5× 32 0.1× 165 0.8× 181 1.1× 199 1.4× 73 1.1k
Yasir Qazi United States 12 261 0.6× 49 0.1× 126 0.6× 95 0.6× 110 0.7× 34 1.0k
Sing Yu Moorcraft United Kingdom 8 723 1.7× 44 0.1× 110 0.6× 371 2.3× 82 0.6× 17 997
Robert P. Sticca United States 19 291 0.7× 48 0.1× 69 0.4× 201 1.2× 151 1.0× 47 1.1k
Kshama Jaiswal United States 13 162 0.4× 120 0.3× 44 0.2× 110 0.7× 145 1.0× 28 741
Anke Rentsch Germany 10 288 0.7× 124 0.4× 74 0.4× 89 0.5× 28 0.2× 22 470
Mehmet Akif Öztürk Türkiye 12 295 0.7× 34 0.1× 49 0.2× 147 0.9× 151 1.0× 40 642

Countries citing papers authored by Ming‐Mo Hou

Since Specialization
Citations

This map shows the geographic impact of Ming‐Mo Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Mo Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Mo Hou more than expected).

Fields of papers citing papers by Ming‐Mo Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Mo Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Mo Hou. The network helps show where Ming‐Mo Hou may publish in the future.

Co-authorship network of co-authors of Ming‐Mo Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Mo Hou. A scholar is included among the top collaborators of Ming‐Mo Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Mo Hou. Ming‐Mo Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chang, John Wen‐Cheng, Jia‐Juan Hsieh, Chih‐Yu Tsai, et al.. (2024). Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer. Biomedical Journal. 47(5). 100698–100698. 14 indexed citations
3.
Teng, Wei, Eric Yi-Liang Shen, Bing‐Shen Huang, et al.. (2024). Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma. The Oncologist. 29(7). e922–e931. 6 indexed citations
4.
Hou, Ming‐Mo, et al.. (2024). Temporal Trends in Survival Outcomes for Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy: A 14-Year Analysis. Annals of Surgical Oncology. 31(10). 6652–6661. 4 indexed citations
5.
6.
Wen, Fur‐Hsing, Chia‐Hsun Hsieh, Po‐Jung Su, et al.. (2023). Factors Associated With Family Surrogate Decisional-Regret Trajectories. Journal of Pain and Symptom Management. 67(3). 223–232.e2. 4 indexed citations
7.
Wen, Fur‐Hsing, Chia‐Hsun Hsieh, Ming‐Mo Hou, et al.. (2023). Decisional-Regret Trajectories From End-of-Life Decision Making Through Bereavement. Journal of Pain and Symptom Management. 66(1). 44–53.e1. 5 indexed citations
8.
Wen, Fur‐Hsing, Chia‐Hsun Hsieh, Wen‐Chi Shen, et al.. (2023). Associations Between Surrogates’ Decisional Regret Trajectories and Bereavement Outcomes. Journal of the National Comprehensive Cancer Network. 21(11). 1141–1148.e2. 1 indexed citations
9.
Chung, Wen‐Hung, Mu-Tzu Chu, Ming‐Mo Hou, et al.. (2023). Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. Biomedicine & Pharmacotherapy. 169. 115928–115928. 7 indexed citations
10.
Shen, Wen‐Chi, Ming‐Mo Hou, Tai‐Lin Huang, et al.. (2022). Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain. Journal of Clinical Nursing. 32(3-4). 539–547. 2 indexed citations
11.
Ren, Zheng, Weijia Fang, Sheng Hu, et al.. (2022). P-25 Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation. Annals of Oncology. 33. S255–S255. 1 indexed citations
12.
Yau, Thomas, Chih‐Hung Hsu, Yoon‐Koo Kang, et al.. (2020). O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study. Annals of Oncology. 31. 233–233. 2 indexed citations
13.
14.
Yau, Thomas, Chiun Hsu, Tae‐You Kim, et al.. (2019). Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology. 71(3). 543–552. 187 indexed citations
15.
Wen, Fur‐Hsing, Jen‐Shi Chen, Po‐Jung Su, et al.. (2018). Terminally Ill Cancer Patients' Concordance Between Preferred Life-Sustaining Treatment States in Their Last Six Months of Life and Received Life-Sustaining Treatment States in Their Last Month: An Observational Study. Journal of Pain and Symptom Management. 56(4). 509–518.e3. 13 indexed citations
16.
Wen, Fur‐Hsing, Jen‐Shi Chen, Wen‐Chi Chou, et al.. (2018). Distinct Patterns of Conjoint Symptom Distress and Functional Impairment in the Last Year of Life Predict Terminally Ill Cancer Patients' Survival. Journal of Pain and Symptom Management. 55(6). 1443–1451.e2. 6 indexed citations
17.
Tang, Siew Tzuh, Fur‐Hsing Wen, Wen‐Cheng Chang, et al.. (2017). Preferences for Life-Sustaining Treatments Examined by Hidden Markov Modeling Are Mostly Stable in Terminally Ill Cancer Patients' Last Six Months of Life. Journal of Pain and Symptom Management. 54(5). 628–636.e2. 10 indexed citations
18.
Tang, Siew Tzuh, Chen Hsiu Chen, Fur‐Hsing Wen, et al.. (2017). Accurate Prognostic Awareness Facilitates, Whereas Better Quality of Life and More Anxiety Symptoms Hinder End-of-Life Care Discussions: A Longitudinal Survey Study in Terminally Ill Cancer Patients' Last Six Months of Life. Journal of Pain and Symptom Management. 55(4). 1068–1076. 37 indexed citations
19.
Chou, Wen‐Chi, Chia-Lin Lee, Tsai‐Sheng Yang, et al.. (2017). Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. Journal of the Formosan Medical Association. 117(2). 153–163. 22 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ho-Yeong Lim Breakdown of academic impact, for papers by Deborah Jaffe Breakdown of academic impact, for papers by Jeremy Jones Breakdown of academic impact, for papers by Weng Ng Breakdown of academic impact, for papers by Yasir Qazi Breakdown of academic impact, for papers by Sing Yu Moorcraft Breakdown of academic impact, for papers by Robert P. Sticca Breakdown of academic impact, for papers by Kshama Jaiswal Breakdown of academic impact, for papers by Anke Rentsch Breakdown of academic impact, for papers by Mehmet Akif Öztürk
Rankless by CCL
2026